Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism

Journal of Biological Chemistry

Volumn 292, Issue 26, 2017, Pages 11055-11069

  Pathak, Preeti ^a   Liu, Hailiang ^a   Boehme, Shannon ^a   Xie, Cen ^b   Krausz, Kristopher W ^b   Gonzalez, Frank ^b   Chiang, John Y L ^a  

^a Northeastern Ohio Medical University   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CHEMICAL ACTIVATION; CROSSTALK; GENE EXPRESSION; GLUCOSE; MAMMALS; METABOLISM; PROTEINS;

FARNESOID X RECEPTORS; FIBROBLAST GROWTH FACTOR; GLUCAGON-LIKE PEPTIDE-1; HEPATIC METABOLISMS; INSULIN SENSITIVITY; PROHORMONE CONVERTASE; PROTEIN RECEPTORS; SYNTHESIS PATHWAYS;

BIOSYNTHESIS;

BILE ACID; CALCIUM ION; CYCLIC AMP; CYTOKINE; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 15; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GROWTH FACTOR; HORMONE RECEPTOR STIMULATING AGENT; INT 767; INT 777; LIPID; OBETICHOLIC ACID; RECEPTOR; TAKEDA G PROTEIN RECEPTOR 5; TAUROCHOLIC ACID; TAUROMURICHOLIC ACID; UNCLASSIFIED DRUG; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; FAT INTAKE; G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID SYNTHESIS; CONTROLLED STUDY; FXR GENE; GENE; GENE EXPRESSION; GLUCOSE METABOLISM; INTESTINAL SECRETION; LIPID DIET; LIPID METABOLISM; LIVER METABOLISM; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN SECRETION; TGR5 GENE; ANIMAL; BIOSYNTHESIS; FAT INTAKE; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; BILE ACIDS AND SALTS; DIETARY FATS; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; LIPID METABOLISM; LIVER; MICE; MICE, KNOCKOUT; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85021683795     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M117.784322     Document Type: Article

References (43)

1. Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., and Staels, B. (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89, 147-191
2. Li, T., and Chiang, J. Y. (2014) Bile acid signaling in metabolic disease and drug therapy. Pharmacol. Rev. 66, 948-983
3. Chiang, J. Y. (2009) Bile acids: regulation of synthesis. J. Lipid Res. 50, 1955-1966
4. Takahashi, S., Fukami, T., Masuo, Y., Brocker, C. N., Xie, C., Krausz, K. W., Wolf, C. R., Henderson, C. J., and Gonzalez, F. J. (2016) Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. J. Lipid Res. 57, 2130-2137
5. Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., Hinuma, S., Fujisawa, Y., and Fujino, M. (2003) A G-protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278, 9435-9440
6. Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., Nakamura, T., Itadani, H., and Tanaka, K. (2002) Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298, 714-719
7. Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., Gerard, R. D., Repa, J. J., Mangelsdorf, D. J., and Kliewer, S. A. (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217-225
8. Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., and Gonzalez, F. J. (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102, 731-744
9. Watanabe, M., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., and Auwerx, J. (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113, 1408-1418
10. Wagner, M., Zollner, G., and Trauner, M. (2011) Nuclear receptors in liver disease. Hepatology 53, 1023-1034
11. Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z. Z., Takahashi, S., Tanaka, N., Desai, D., Amin, S. G., Albert, I., Patterson, A. D., and Gonzalez, F. J. (2015) Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125, 386-402
12. Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., Liu, Y., Gavrilova, O., Patterson, A. D., and Gonzalez, F. J. (2015) Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6, 10166
13. Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., Atkins, A. R., Khvat, A., Schnabl, B., Yu, R. T., Brenner, D. A., et al. (2015) Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21, 159-165
14. Keitel, V., Donner, M., Winandy, S., Kubitz, R., and Häussinger, D. (2008) Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem. Biophys. Res. Commun. 372, 78-84
15. Katsuma, S., Hirasawa, A., and Tsujimoto, G. (2005) Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 329, 386-390
16. Harach, T., Pols, T. W., Nomura, M., Maida, A., Watanabe, M., Auwerx, J., and Schoonjans, K. (2012) TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci. Rep. 2, 430
17. Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., and Habener, J. F. (1986) Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol. Chem. 261, 11880-11889
18. Fehmann, H. C., and Habener, J. F. (1992) Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma TC-1 cells. Endocrinology 130, 159-166
19. Parker, H. E., Wallis, K., le Roux, C. W., Wong, K. Y., Reimann, F., and Gribble, F. M. (2012) Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br. J. Pharmacol. 165, 414-423
20. Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., Pellicciari, R., Auwerx, J., and Schoonjans, K. (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10, 167-177
21. Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., Schoonjans, K., Bianco, A. C., and Auwerx, J. (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439, 484-489
22. Donepudi, A. C., Boehme, S., Li, F., and Chiang, J. Y. (2017) G-proteincoupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. Hepatology 65, 813-827
23. Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Jr., Parés, A., Trauner, M., Marschall, H. U., Adorini, L., Sciacca, C., Beecher-Jones, T., et al. (2015) Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148, 751-761, e8
24. Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., Kowdley, K. V., McCullough, A., Terrault, N., Clark, J. M., Tonascia, J., et al. (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956-965
25. Rizzo, G., Passeri, D., De Franco, F., Ciaccioli, G., Donadio, L., Rizzo, G., Orlandi, S., Sadeghpour, B., Wang, X. X., Jiang, T., Levi, M., Pruzanski, M., and Adorini, L. (2010) Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol. Pharmacol. 78, 617-630
26. McMahan, R. H., Wang, X. X., Cheng, L. L., Krisko, T., Smith, M., El Kasmi, K., Pruzanski, M., Adorini, L., Golden-Mason, L., Levi, M., and Rosen, H. R. (2013) Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J. Biol. Chem. 288, 11761-11770
27. Miyazaki-Anzai, S., Masuda, M., Levi, M., Keenan, A. L., and Miyazaki, M. (2014) Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. PLoS One 9, e108270
28. Xu, Y., Li, F., Zalzala, M., Xu, J., Gonzalez, F. J., Adorini, L., Lee, Y. K., Yin, L., and Zhang, Y. (2016) Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology 64, 1072-1085
29. Trabelsi, M. S., Daoudi, M., Prawitt, J., Ducastel, S., Touche, V., Sayin, S. I., Perino, A., Brighton, C. A., Sebti, Y., Kluza, J., Briand, O., Dehondt, H., Vallez, E., Dorchies, E., Baud, G., et al. (2015) FarnesoidXreceptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat. Commun. 6, 7629
30. Düfer, M., Hörth, K., Wagner, R., Schittenhelm, B., Prowald, S., Wagner, T. F., Oberwinkler, J., Lukowski, R., Gonzalez, F. J., Krippeit-Drews, P., and Drews, G. (2012) Bile acids acutely stimulate insulin secretion of mouse beta-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes 61, 1479-1489
31. Renga, B., Mencarelli, A., Vavassori, P., Brancaleone, V., and Fiorucci, S. (2010) The bile acid sensor FXR regulates insulin transcription and secretion. Biochim. Biophys. Acta 1802, 363-372
32. Li, T., Francl, J. M., Boehme, S., Ochoa, A., Zhang, Y., Klaassen, C. D., Erickson, S. K., and Chiang, J. Y. (2012) Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J. Biol. Chem. 287, 1861-1873
33. Haeusler, R. A., Astiarraga, B., Camastra, S., Accili, D., and Ferrannini, E. (2013) Human insulin resistance is associated with increased plasma levels of 12-hydroxylated bile acids. Diabetes 62, 4184-4191
34. Li, T., Owsley, E., Matozel, M., Hsu, P., Novak, C. M., and Chiang, J. Y. (2010) Transgenic expression of cholesterol 7-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 52, 678-690
35. Ryan, K. K., Tremaroli, V., Clemmensen, C., Kovatcheva-Datchary, P., Myronovych, A., Karns, R., Wilson-Pérez, H. E., Sandoval, D. A., Kohli, R., Bäckhed, F., and Seeley, R. J. (2014) FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509, 183-188
36. McGavigan, A. K., Garibay, D., Henseler, Z. M., Chen, J., Bettaieb, A., Haj, F. G., Ley, R. E., Chouinard, M. L., and Cummings, B. P. (2017) TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice. Gut 66, 226-234
37. Patti, M. E., Houten, S. M., Bianco, A. C., Bernier, R., Larsen, P. R., Holst, J. J., Badman, M. K., Maratos-Flier, E., Mun, E. C., Pihlajamaki, J., Auwerx, J., and Goldfine, A. B. (2009) Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity 17, 1671-1677
38. Simonen, M., Dali-Youcef, N., Kaminska, D., Venesmaa, S., Käkelä, P., Pääkkönen, M., Hallikainen, M., Kolehmainen, M., Uusitupa, M., Moilanen, L., Laakso, M., Gylling, H., Patti, M. E., Auwerx, J., and Pihlajamäki, J. (2012) Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes. Surg. 22, 1473-1480
39. Baghdasaryan, A., Claudel, T., Gumhold, J., Silbert, D., Adorini, L., Roda, A., Vecchiotti, S., Gonzalez, F. J., Schoonjans, K., Strazzabosco, M., Fickert, P., and Trauner, M. (2011) Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2/ (Abcb4/) mouse cholangiopathy model by promoting biliary HCO output. Hepatology 54, 1303-1312
40. Vassileva, G., Golovko, A., Markowitz, L., Abbondanzo, S. J., Zeng, M., Yang, S., Hoos, L., Tetzloff, G., Levitan, D., Murgolo, N. J., Keane, K., Davis, H. R., Jr, Hedrick, J., and Gustafson, E. L. (2006) Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem. J. 398, 423-430
41. Li, F., Jiang, C., Krausz, K. W., Li, Y., Albert, I., Hao, H., Fabre, K. M., Mitchell, J. B., Patterson, A. D., and Gonzalez, F. J. (2013) Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun. 4, 2384
42. Brubaker, P. L., Schloos, J., and Drucker, D. J. (1998) Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology 139, 4108-4114
43. Li, T., and Chiang, J. Y. (2007) A novel role of transforming growth factor 1 in transcriptional repression of human cholesterol 7-hydroxylase gene. Gastroenterology 133, 1660-1669